虚血性脳卒中の世界市場：市場規模 - 診断別、薬物クラス別、手術別、エンドユーザー別、地域別展望、競合戦略、セグメント別予測（～2032年）

世界の虚血性脳卒中の市場規模は、2032年までに135億4,000万米ドルに達し、CAGRで4.24%の成長が予測されています。

健康意識の高まり、糖尿病患者の増加、タバコ使用量の増加、人口の高齢化などの要因によって市場は牽引されています。虚血性脳卒中の検出や治療法に関する新開発技術の進展も、市場の成長に寄与しています。

当レポートでは、世界の虚血性脳卒中市場について調査し、市場力学、市場変数と展望、診断・薬物クラス・手術・エンドユーザー・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

• 調査範囲
• 市場セグメント分析

第2章 調査手法

• 調査データソース
• 市場規模の推定
• データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因、抑制要因、機会、課題の分析
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• 世界の虚血性脳卒中市場におけるCOVID-19の影響

第5章 市場変数と展望

• SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • 社会情勢
  • 技術情勢
  • 環境情勢
  • 法的情勢
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入者の脅威
  • 競合企業間の敵対関係
• ヒートマップ分析

第6章 世界の虚血性脳卒中市場：診断別（2019年～2032年（100万米ドル））

• 頸動脈超音波
• 大脳超音波
• 複合血管造影
• 心エコー図
• 心電図
• 磁気共鳴画像
• その他

第7章 世界の虚血性脳卒中市場：薬物クラス別（2019年～2032年（100万米ドル））

• 組織プラスミノーゲンアクチベーター
• 抗凝固剤
• 抗血小板剤
• 降圧剤
• その他

第8章 世界の虚血性脳卒中市場：手術別（2019年～2032年（100万米ドル））

• 血管形成術
• 頸動脈内膜剥離術
• 血管内機械的血栓除去術

第9章 世界の虚血性脳卒中市場：エンドユーザー別（2019年～2032年（100万米ドル））

• 病院・クリニック
• 医療機関
• 研究機関
• その他

第10章 世界の虚血性脳卒中市場：地域別（2019年～2032年（100万米ドル））

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• 中東・アフリカ
  • サウジアラビア王国
  • アラブ首長国連邦
  • その他の中東・アフリカ

第11章 企業プロファイル

• Abott Laboratories
  • 企業概要
  • 財務展望
  • 製品概要
  • 最近の開発
• Bayer AG
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien plc
• GE Healthcare
• Genentech, Inc.
• Jhonson & Jhonson
• Koninklijke Philips N.V.
• Medtronic plc
• Merck & Co. Inc.
• Philips Healthcare
• Sanofi
• Stryker Corporation

Global Ischemic Stroke Market Overview:

According to SPER Market Research, the Global Ischemic Stroke Market is estimated to reach USD 13.54 billion by 2032 with a CAGR of 4.24%.

Strokes can also happen when the blood supply to the brain is cut off. Strokes frequently happen when a blood vessel in the brain rupture, allowing haemorrhage to escape. This fracture, or any other sort of obstruction, prevented the blood and oxygen from reaching the brain tissues. Transient ischemic attack (TIA), haemorrhagic stroke, or ischemic stroke are the three main types of strokes that affect everyone in the globe. This procedure uses popular diagnostic tools like echocardiograms, MRIs, CT scans, cerebral angiograms, and blood tests. Treatments for this condition include aspirin, other antiplatelet medications, and anticoagulants.The market for ischemic stroke is being driven by factors such increased health awareness, rising diabetes rates, a rise in tobacco use, and an ageing population. However, the development of new developing technologies for ischemic stroke detection and treatment methods also contributes to the market growth. The maximum amount of blood typically stops abruptly reaching certain parts of the brain, which is how an ischemic stroke usually happens. The region and mechanism of ischemic strokes can be separated. Depending on how they grow within the bodily components, all blood clots inside the body are either thrombotic or embolic.There are expected to be significant growth opportunities in the market for acute ischemic stroke diagnosis and treatment as a result of increased public awareness of stroke and the range of market-available treatments, encouraging government initiatives, and the quickening pace of technological advancements in surgical procedures.The market for the diagnosis and treatment of acute ischemic stroke is expected to grow, but this is expected to be constrained by the high cost of care and the unfavourable reimbursement environment. Additionally, there may be challenges due to the numerous issues associated with product development and manufacturing.

Impact of COVID-19 on the Global Ischemic Stroke Market

According to the Ischemic Stroke market analysis, the virus known as the severity of acute respiratory syndrome of coronavirus 2 that is spread within people is the cause of this condition. Additionally, there has been a slight decline in hospital sectors as a result of the COVID-19 pandemic. It was as a result of individuals becoming afraid of the infection during the lockdown and distance-keeping phase. For health emergencies, a number of nations imposed a rigorous lockdown on their territory. The international trade and business sectors have been suspended for a while. The need for cutting-edge medical equipment has already increased during the lockdown.The COVID-19 has had a direct impact on the global hospital and healthcare industries. Overall, the disease had a very seriously detrimental effect on the market value for ischemic strokes. Investors have suffered a significant loss as a result of the decline in production and manufacturing work. Furthermore, because of several hospital-based therapies for ischemic stroke patients, the major companies in this business are obligated to cut their investment in raw materials and resources. It is also one of the most crucial things to go through at this difficult time. Since every worldwide industry has been severely impacted by this epidemic, most manufacturers aim to satisfy the needs of many industries.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Diagnosis, By Drug Class, By Surgery, By End User

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Abott Laboratories, Bayer AG, Boehringer Ingelheim, Boston Scientific Corporation, Cordis Corporation, Covidien plc, GE Healthcare, Genentech, Inc., Jhonson & Jhonson, Koninklijke Philips N.V., Medtronic plc, Merck & Co., Inc., Philips Healthcare, Sanofi, Stryker Corporation

Global Ischemic Stroke Market Segmentation:

By Diagnosis: Based on the Diagnosis, Global Ischemic Stroke Market is segmented as; Carotid Ultrasound, Cerebral Angiography, Computed Tomography, Echocardiography, Electrocardiography, Magnetic Resonance Imaging, Others.

By Drug Class: Based on the Drug Class, Global Ischemic Stroke Market is segmented as; Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive, Others.

By Surgery: Based on the Surgery, Global Ischemic Stroke Market is segmented as; Angioplasty, Carotid Endarterectomy, Endovascular Mechanical Thrombectomy.

By End User: Based on the End User, Global Ischemic StrokeMarket is segmented as; Hospitals & Clinic, Medical Institutes, Research Organization, Others.

By Region: Due to rapid technological improvement in the acute ischemic stroke treatment process and supportive government policies, the North American area dominates the acute ischemic stroke diagnosis and treatment market. Because of the rise in ischemic stroke Asia-Pacific is anticipated to develop much faster than the global average.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1 Research data source
  • 2.1.1 Secondary data
  • 2.1.2 Primary data
  • 2.1.3 SPER's internal database
  • 2.1.4 Premium insight from KOL's
• 2.2 Market size estimation
  • 2.2.1 Top-down and Bottom-up approach
• 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1 Drivers
  • 4.1.2 Restraints
  • 4.1.3 Opportunities
  • 4.1.4 Challenges
• 4.2. COVID-19 Impacts of the Global Ischemic Stroke Market

5. Market variables and outlook

• 5.1. SWOT analysis
  • 5.1.1 Strengths
  • 5.1.2 Weaknesses
  • 5.1.3 Opportunities
  • 5.1.4 Threats
• 5.2. PESTEL analysis
  • 5.2.1 Political landscape
  • 5.2.2 Economic landscape
  • 5.2.3 Social landscape
  • 5.2.4 Technological landscape
  • 5.2.5 Environmental landscape
  • 5.2.6 Legal landscape
• 5.3. PORTER'S five forces analysis
  • 5.3.1 Bargaining power of suppliers
  • 5.3.2 Bargaining power of Buyers
  • 5.3.3 Threat of Substitute
  • 5.3.4 Threat of new entrant
  • 5.3.5 Competitive rivalry
• 5.4. Heat map analysis

6. Global Ischemic Stroke Market, By Diagnosis, 2019-2032 (USD Million)

• 6.1. Carotid Ultrasound
• 6.2. Cerebral Ultrasound
• 6.3. Compound Angiography
• 6.4. Echocardiography
• 6.5. Electrocardiography
• 6.6. Magnetic Resonance Imaging
• 6.7. Others

7. Global Ischemic Stroke Market, By Drug Class, 2019-2032 (USD Million)

• 7.1. Tissue Plasminogen Activator
• 7.2. Anticoagulant
• 7.3. Antiplatelet
• 7.4. Antihypertensive
• 7.5. Others

8. Global Ischemic Stroke Market, By Surgery, 2019-2032 (USD Million)

• 8.1. Angioplasty
• 8.2. Carotid Endarterectomy
• 8.3. Endovascular Mechanical Thrombectomy

9. Global Ischemic Stroke Market, By End User, 2019-2032 (USD Million)

• 9.1. Hospitals & Clinic
• 9.2. Medical Institutes
• 9.3. Research Organization
• 9.4. Others

10. Global Ischemic Stroke Market, By Region, 2019-2032 (USD Million)

• 10.1. North America
  • 10.1.1. United States
  • 10.1.2. Canada
  • 10.1.3. Mexico
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. United Kingdom
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. South Korea
  • 10.3.6. Rest of Asia-Pacific
• 10.4. South America
  • 10.4.1. Brazil
  • 10.4.2. Argentina
  • 10.4.3. Rest of South America
• 10.5. Middle East & Africa
  • 10.5.1. Kingdom of Saudi Arabia
  • 10.5.2. United Arab Emirates
  • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

• 11.1. Abott Laboratories
  • 11.1.1. Company details
  • 11.1.2. Financial outlook
  • 11.1.3. Product summary
  • 11.1.4. Recent developments
• 11.2. Bayer AG
  • 11.2.1. Company details
  • 11.2.2. Financial outlook
  • 11.2.3. Product summary
  • 11.2.4. Recent developments
• 11.3. Boehringer Ingelheim
  • 11.3.1. Company details
  • 11.3.2. Financial outlook
  • 11.3.3. Product summary
  • 11.3.4. Recent developments
• 11.4. Boston Scientific Corporation
  • 11.4.1. Company details
  • 11.4.2. Financial outlook
  • 11.4.3. Product summary
  • 11.4.4. Recent developments
• 11.5. Cordis Corporation
  • 11.5.1. Company details
  • 11.5.2. Financial outlook
  • 11.5.3. Product summary
  • 11.5.4. Recent developments
• 11.6. Covidien plc
  • 11.6.1. Company details
  • 11.6.2. Financial outlook
  • 11.6.3. Product summary
  • 11.6.4. Recent developments
• 11.7. GE Healthcare
  • 11.7.1. Company details
  • 11.7.2. Financial outlook
  • 11.7.3. Product summary
  • 11.7.4. Recent developments
• 11.8. Genentech, Inc.
  • 11.8.1. Company details
  • 11.8.2. Financial outlook
  • 11.8.3. Product summary
  • 11.8.4. Recent developments
• 11.9. Jhonson&Jhonson
  • 11.9.1. Company details
  • 11.9.2. Financial outlook
  • 11.9.3. Product summary
  • 11.9.4. Recent developments
• 11.10. Koninklijke Philips N.V.
  • 11.10.1. Company details
  • 11.10.2. Financial outlook
  • 11.10.3. Product summary
  • 11.10.4. Recent developments
• 11.11. Medtronic plc
  • 11.11.1. Company details
  • 11.11.2. Financial outlook
  • 11.11.3. Product summary
  • 11.11.4. Recent developments
• 11.12. Merck & Co. Inc.
  • 11.12.1. Company details
  • 11.12.2. Financial outlook
  • 11.12.3. Product summary
  • 11.12.4. Recent developments
• 11.13. Philips Healthcare
  • 11.13.1. Company details
  • 11.13.2. Financial outlook
  • 11.13.3. Product summary
  • 11.13.4. Recent developments
• 11.14. Sanofi
  • 11.14.1. Company details
  • 11.14.2. Financial outlook
  • 11.14.3. Product summary
  • 11.14.4. Recent developments
• 11.15. Stryker Corporation
  • 11.15.1. Company details
  • 11.15.2. Financial outlook
  • 11.15.3. Product summary
  • 11.15.4. Recent developments